Botanical species · safety record

Cullen corylifolium

The EFSA Compendium of Botanicals holds 15 constituent measurements and 3 adverse-effect records for Cullen corylifolium. This page reports what those source records contain and how to reach them. It carries no effect estimate, no dose and no recommendation.

Accepted name in source: Cullen corylifolium (L.) Medik.

15Constituent measurements

3Safety records

6Cited sources

183Licensed products (Canada)

Also recorded as

Psoralea corylifolia L.

Synonyms are carried from the source compendium. A species may be traded and studied under more than one name, which is exactly how a safety record gets lost.

Regulatory presence

Health Canada's Licensed Natural Health Products Database holds 183 licensed products naming Cullen corylifolium as a medicinal ingredient, matched on the exact Latin binomial. A licence records that a product met the regulator's requirements for sale in Canada. It is not evidence that the product works.

Extract types on licence

Dry
Extract Type TBA

Source material stated

Fruit
Fruit (processed with salt)
Fruit (stir-baked with Semen Sesami Nigrum)
Fruit extract
New material
Ripe fruit(s)
Seed extract
Seed(s)

What the records describe

Constituents measured

Plant parts

Preparations

Effect types

Target tissues

Recorded constituents

What analytical work has found in this species, at which plant part and preparation. A measured constituent is a fact about material, not about effect.

Substance	Plant part	Preparation	Concentration	Analytical method	Source
Angelicin	Leaves	Solvent extraction	110 Microgram/gram	HPLC with standard detection methods	Resolve DOI
Bakuchiol	Seed	Solvent extraction	7.5 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Furanocoumarins	Seed	Solvent extraction	15.6 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Furanocoumarins	Seed	Solvent extraction	7.8 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Furanocoumarins	Seed	Solvent extraction	10.5 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Psoralen	Leaves	Solvent extraction	205 Microgram/gram	HPLC with standard detection methods	Resolve DOI
Psoralen	Seed	Solvent extraction	≥ 21.7 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
Psoralen	Seed	Solvent extraction	≤ 26.8 Milligram/gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	Resolve DOI
4-hydroxybenzaldehyde	Seed	Solvent extraction	—	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Angelicin	Seed	Solvent extraction	0.34 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Angelicin	Seed	Solvent extraction	2431.81 Milligram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Bakuchiol	Seed	Solvent extraction	—	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Bergapten	Seed	Solvent extraction	16.14 Milligram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Psoralen	Seed	Solvent extraction	2741.68 Milligram/100 gram	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier
Psoralen	Seed	Solvent extraction	0.39 Percent	High Performance Liquid Chromatography (HPLC)/Liquid Chromatography (LC)	No resolvable identifier

Recorded adverse effects

Adverse effects reported in the source literature, most often in animal or laboratory models at a stated preparation and dose.

Effect	Target tissue	Plant part	Preparation	Test organism	Test type	Source
Hepatotoxicity	Liver	Seed	—	Human (as organism)	Case report	Resolve DOI
Hepatotoxicity	Liver	Seed	Solvent extraction	Rat (as animal)	Short-term toxicity	Resolve DOI
Hepatotoxicity	Liver	Seed	Solvent extraction	Rat (as animal)	Short-term toxicity	Resolve DOI

Cited sources

The literature the compendium cites for this species. Metatron Health has no relationship with these authors or journals and earns nothing from citing them.

Kim, Ho Kyoung., Lee, Hye Won., Chun, Jin Mi., Lee, A. Yeong., Ko, Byoung Seob. Quantitative analysis of psoralen and angelicin in the Psoraleae Semen and processed Psoraleae Semen. Saengyak hakhoechi, 2004, vol. 35, no. 3, p. 179-183.
Jeong, Dami., Watari, Kousuke., Shirouzu, Takayuki., Ono, Mayumi., Koizumi, Keiichi., Saiki, Ikuo., Kim, Youn-Chul., Tanaka, Chiaki., Higuchi, Ryuichi., Miyamoto, Tomofumi. Studies on Lymphangiogenesis Inhibitors from Korean and Japanese Crude Drugs . Biological & pharmaceutical bulletin, 2013, vol. 36, no. 1, p. 152-157.
Wang, Jiaying., Jiang, Zhenzhou., Ji, Jinzi., Li, Yanyan., Chen, Mi., Wang, Yurong., Zhang, Yun., Tai, Ting., Wang, Tao., Zhang, Luyong. Evaluation of hepatotoxicity and cholestasis in rats treated with EtOH extract of Fructus Psoraleae . Journal of ethnopharmacology, 2012, vol. 144, no. 1, p. 73-81. DOI
Harsahay, M., Hemant Kr, P., Aarti, M., Mohd., N. Development of HPLC method for estimation of furonocumarins in Psoralea corylifolia and Ammi majus. International journal of pharmacognosy and phytochemical research, 2014, vol. 6, no. 2, p. 290-294.
BOURGAUD, F., GRIMAL, JY., NGUYEN, C., BITTON, G., GUCKERT, A. A SELECTIVE PHOTOBIOLOGICAL ASSAY TO DETECT AND QUANTIFY PSORALEN IN PSORALEA PLANTS (LEGUMINOSAE) . Phytochemical analysis, 1994, vol. 5, no. 6, p. 315-318. DOI
Chitturi, S., Farrell, G.C. Hepatotoxic slimming aids and other herbal hepatotoxins. Journal of gastroenterology and hepatology (australia), 2008, vol. 23, no. 3, p. 366-373. DOI

Boundary

A constituent measurement is a fact about material at a stated preparation, not a statement about what that material does in a person. An adverse-effect or genotoxicity record is an observation reported in a source, most often in an animal or laboratory model. Neither is a Metatron Health conclusion about causality, human risk or benefit, and the absence of a record is not proof that a preparation is safe. Nothing here is diagnosis, prescribing or individual medical care.

Continue

Independent literature